"Tinofara kuunza iyi yakakosha yebiologic kurapwa kune vekuCanada vanorarama nechirwere ichi chakajairika, chinodzivirira uye chinowanzo furatirwa. Kuvhurwa uku chiitiko chakakosha cheSun Pharma, apo isu tichiwedzera dermatology portfolio muCanada, "akadaro Abhay Gandhi, CEO North America, Sun Pharma. "Nemakore mashanu ekurapa kwakanaka kwepakati-kusvika-yakaoma plaque psoriasis, ILUMYA inoratidza kuzvipira kwedu mukupa mishonga yehunyanzvi kutsigira mararamiro evarwere uye sarudzo yachiremba."
Plaque psoriasis chirwere chisingaperi chinoratidzika paganda sechitsvuku, nzvimbo dzakasimudzwa dzeganda dzakafukidzwa nemakwande machena anogona kutsemuka uye kubuda ropa. Inobata vanhu vangangoita miriyoni imwe chete vekuCanada. Pakati-kusvika-yakaoma plaque psoriasis inokanganisa vanenge 35% yevarwere. Dambudziko guru nderekuti marapirwo mazhinji anomira kushanda nguva yakawandisa uye zviratidzo zvinodzoka. Kugara kwenguva refu kwekurapa kwenguva refu chinhu chisina kukwana chevarwere vazhinji.
"Plaque psoriasis ine mwero-kusvika-yakaoma inogona kuita kuti zviome kunzwa wakasununguka paganda rako pachako uye kutsvaga kurapwa kunoshanda kunogona kunge kwakaoma sechirwere chacho pachacho," akadaro Dr. Melinda Gooderham, chiremba ane chitupa cheDermatologist uye Medical Director. pa SKiN Center yeDermatology muPeterborough, Ontario. "Varwere vedu vanoda sarudzo dzekurapa kunoshanda, kwakasimba uye kunoramba kuripo muCanada uye ILUMYA ichabatsira kuzadzisa icho chinodiwa."
Mune yakadhindwa nevezera yakaongororwa magazini yeakaunganidzwa kuongororwa kweyedzo mbiri reSURFACE 1 uye reSURFACE 2, iyo data inoratidza kuti varwere vazhinji paILUMYA vakachengeta mhinduro uye inosimbisa kuchengetedza nhoroondo kuburikidza ne5 makore ekurapwa.
Mune varwere vakabatwa neILUMYA 100 mg, vanenge mapfumbamwe kubva pa10 vakachengetedza mhinduro yavo kuburikidza neGore 5. ILUMYA 100 mg yakanyatsobvumirwa panguva yeChikamu 3 miedzo. Maitiro matatu akashata akaitika kakawanda kupfuura placebo uye ≥1% mumakiriniki ekuedzwa aive epamusoro kufema zvirwere (15.1% vs. 12.3%), jekiseni site reactions (3.9% vs. 2.6%) uye musoro (3.2% vs. 2.9% )
MuCanada, vamwe varwere vanobatanidzwa muchidzidzo ichi vakataura kuti vachiri neganda rakajeka makore masere gare gare.
“Ndine varwere vakarapwa neILUMYA kwemakore masere apfuura, uye ndakaona ganda ravo richivandudzika kusvika padanho repamusoro, uye kugara rakajeka kwenguva refu. Somugumisiro, upenyu hwavo hwava nani,” akawedzera kudaro Dr. Gooderham.
“Upenyu hwangu hwose ndaitambura nechirwere che<em>plaque psoriasis chiri pakati nepakati kusvika kune chakaoma, uye ndaigara ndichitenderedza pakati pemafuta nemafuta asingamboshandi uye zvaingowedzera kushushikana kwangu. Kusvika ndaziva nezve ILUMYA, ndaifunga kuti ndakanga ndapererwa nesarudzo, "akadaro Ainsley Leween, murwere we psoriasis. "Kubva pandakatanga kushandisa ILUMYA makore masere apfuura, psoriasis yangu yanga ichidzora."
Canadian Agency for Drugs and Technologies in Health (CADTH), kuburikidza neCommon Drug Review, yakurudzira zvakanaka kumatunhu ainobata nawo kuti chigadzirwa cheILUMYA chidzoserwe kuvarwere vane plaque psoriasis ine mwero-kusvika-yakaoma, kana yarairwa nachiremba weganda.
ZVOKUBVA MUNYAYA INO:
- Mune yakadhindwa nevezera yakaongororwa magazini yeakaunganidzwa kuongororwa kweyedzo mbiri reSURFACE 1 uye reSURFACE 2, iyo data inoratidza kuti varwere vazhinji paILUMYA vakachengeta mhinduro uye inosimbisa kuchengetedza nhoroondo kuburikidza ne5 makore ekurapwa.
- Canadian Agency for Drugs and Technologies in Health (CADTH), kuburikidza neCommon Drug Review, yakurudzira zvakanaka kumatunhu ainobata nawo kuti chigadzirwa cheILUMYA chidzoserwe kuvarwere vane plaque psoriasis ine mwero-kusvika-yakaoma, kana yarairwa nachiremba weganda.
- “Moderate-to-severe plaque psoriasis can make it difficult to feel comfortable in your own skin and the search for an effective treatment can be as challenging as the disease itself,”.
